肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

SCI REP：术中芬太尼用量不会影响结直肠癌患者预后

2017-09-08 MedSci MedSci原创

结直肠癌芬太尼预后
关注

阿片类药物是治疗肿瘤相关疼痛及围手术期急性疼痛的主要止痛药。但是有研究表明阿片类药物会抑制人体细胞及体液免疫功能。尽管目前尚无直接证据证明阿片类在肿瘤发生中的作用，但是动物模型中已发现其可能会导致肿瘤复发。芬太尼也有同样的促肿瘤特性。SCI REP近期发表了一篇文章，研究术中芬太尼用量对结直肠癌患者预后的影响。

阿片类药物是治疗肿瘤相关疼痛及围手术期急性疼痛的主要止痛药。但是有研究表明阿片类药物会抑制人体细胞及体液免疫功能。尽管目前尚无直接证据证明阿片类在肿瘤发生中的作用，但是动物模型中已发现其可能会导致肿瘤复发。芬太尼也有同样的促肿瘤特性。SCI REP近期发表了一篇文章，研究术中芬太尼用量对结直肠癌患者预后的影响。研究共回顾性分析了2011年1月到2014年12月之间共1679例Ⅰ-Ⅲ期接受肿瘤切除的结直肠癌患者。利用风险回归模型分析术后无复发生存和总生存情况。研究结果表明芬太尼用量与无复发生存和总生存之间无剂量依赖联系。通过平均芬太尼用量将患者分为高剂量组和低剂量组，两组间无复发生存和总生存无显着区别。文章最后认为，术中芬太尼用量对结直肠癌患者肿瘤切除后无复发生存或总生存无影响。原始出处：Ying-Hsuan Tai,Hsiang-Ling Wu,et al.Intraoperative Fentanyl Consumption Does Not Impact Cancer Recurrence or Overall Survival after Curative Colorectal

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1691925, encodeId=a1bb16919251b, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Sat Aug 11 05:23:00 CST 2018, time=2018-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=242636, encodeId=1e00242636e3, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Sun Sep 10 21:48:10 CST 2017, time=2017-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384803, encodeId=a9951384803c0, content=<a href='/topic/show?id=93918690e81' target=_blank style='color:#2F92EE;'>#芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86907, encryptionId=93918690e81, topicName=芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Sun Sep 10 00:23:00 CST 2017, time=2017-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452976, encodeId=562914529e668, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Sun Sep 10 00:23:00 CST 2017, time=2017-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=241727, encodeId=562f241e27ad, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋，懒，贪, createdTime=Fri Sep 08 10:27:00 CST 2017, time=2017-09-08, status=1, ipAttribution=)]
    2018-08-11 bnurmamat

    #患者预后#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1691925, encodeId=a1bb16919251b, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Sat Aug 11 05:23:00 CST 2018, time=2018-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=242636, encodeId=1e00242636e3, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Sun Sep 10 21:48:10 CST 2017, time=2017-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384803, encodeId=a9951384803c0, content=<a href='/topic/show?id=93918690e81' target=_blank style='color:#2F92EE;'>#芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86907, encryptionId=93918690e81, topicName=芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Sun Sep 10 00:23:00 CST 2017, time=2017-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452976, encodeId=562914529e668, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Sun Sep 10 00:23:00 CST 2017, time=2017-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=241727, encodeId=562f241e27ad, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋，懒，贪, createdTime=Fri Sep 08 10:27:00 CST 2017, time=2017-09-08, status=1, ipAttribution=)]
    2017-09-10 luominglian113

    学习了.谢谢分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1691925, encodeId=a1bb16919251b, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Sat Aug 11 05:23:00 CST 2018, time=2018-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=242636, encodeId=1e00242636e3, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Sun Sep 10 21:48:10 CST 2017, time=2017-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384803, encodeId=a9951384803c0, content=<a href='/topic/show?id=93918690e81' target=_blank style='color:#2F92EE;'>#芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86907, encryptionId=93918690e81, topicName=芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Sun Sep 10 00:23:00 CST 2017, time=2017-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452976, encodeId=562914529e668, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Sun Sep 10 00:23:00 CST 2017, time=2017-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=241727, encodeId=562f241e27ad, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋，懒，贪, createdTime=Fri Sep 08 10:27:00 CST 2017, time=2017-09-08, status=1, ipAttribution=)]
    2017-09-10 xue8602

    #芬太尼#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1691925, encodeId=a1bb16919251b, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Sat Aug 11 05:23:00 CST 2018, time=2018-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=242636, encodeId=1e00242636e3, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Sun Sep 10 21:48:10 CST 2017, time=2017-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384803, encodeId=a9951384803c0, content=<a href='/topic/show?id=93918690e81' target=_blank style='color:#2F92EE;'>#芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86907, encryptionId=93918690e81, topicName=芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Sun Sep 10 00:23:00 CST 2017, time=2017-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452976, encodeId=562914529e668, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Sun Sep 10 00:23:00 CST 2017, time=2017-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=241727, encodeId=562f241e27ad, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋，懒，贪, createdTime=Fri Sep 08 10:27:00 CST 2017, time=2017-09-08, status=1, ipAttribution=)]
    2017-09-10 crystal0564

    #结直肠#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1691925, encodeId=a1bb16919251b, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Sat Aug 11 05:23:00 CST 2018, time=2018-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=242636, encodeId=1e00242636e3, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=550d2008262, createdName=luominglian113, createdTime=Sun Sep 10 21:48:10 CST 2017, time=2017-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1384803, encodeId=a9951384803c0, content=<a href='/topic/show?id=93918690e81' target=_blank style='color:#2F92EE;'>#芬太尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86907, encryptionId=93918690e81, topicName=芬太尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Sun Sep 10 00:23:00 CST 2017, time=2017-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1452976, encodeId=562914529e668, content=<a href='/topic/show?id=098ee8679ad' target=_blank style='color:#2F92EE;'>#结直肠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78679, encryptionId=098ee8679ad, topicName=结直肠)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9ace5575596, createdName=crystal0564, createdTime=Sun Sep 10 00:23:00 CST 2017, time=2017-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=241727, encodeId=562f241e27ad, content=谢谢分享.学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Q3auHgzwzM7GibvIBibibnnnvpajk2stlDF5oichYahI6Bia8uxeTBFoPbdoHWebyXf9eal9FNgUF2lNcrwoZicM3BvQ/0, createdBy=a3742066385, createdName=戒馋，懒，贪, createdTime=Fri Sep 08 10:27:00 CST 2017, time=2017-09-08, status=1, ipAttribution=)]
    2017-09-08 戒馋，懒，贪

    谢谢分享.学习了

    0

相关资讯

Biomed Res Int：研究发现H19促进结直肠癌细胞增殖的机制

H19是一种父系遗传的非编码RNA，多种癌症中过度表达，包括结直肠癌（CRC），且或可作为癌基因。然而，CRC的进展过程中H19的调控机制仍知之甚少。本研究旨在评估H19在CRC组织中的表达水平，确定H19对CRC增殖的影响，并探讨H19调控CRC增殖的机制。采用qRT-PCR研究人员评估了H19的表达，并通过细胞生长曲线、细胞存活率检测及克隆形成试验分析H19对结肠癌细胞增殖的影响。为阐明这些影

盘点：结直肠癌研究进展一览

结直肠癌是我国最为常见的癌症之一，近年来发病率呈不断上升的趋势，尤其在一些地区年龄超过50岁的人，更是肠癌的多发人群，不论男女，结肠癌与直肠癌的发病比例约各占其半。而且城市远高于农村，多数患者发现时已属于中晚期。梅斯医学小编整理了关于结直肠癌的最新研究进展，与大家分享！ 【1】Lancet Oncol：TAS-102+贝伐单抗可用于治疗难治性的转移性结直肠癌 http：//www.

Ann Oncol：长链非编码RNA——CCAT1和CCAT2表达的改变，是结直肠癌预后的重要标志物

在结直肠癌（CRC）中，基因组区域8q24.21经常表现出多态性。这个区域由于缺乏重要的蛋白质编码基因，通常被称为“基因沙漠”，它突出了非编码RNA的潜在作用，包括位于原癌基因MYM周围的长链非编码RNA（lncRNA）。

Int J Cancer：粪便微生物标志物在结直肠癌检测中的应用

结直肠癌（Colorectal Cancer，CRC）是西方世界第二大导致癌症死亡的原因。CRC在多数情况下，基因组的突变，如APC/wnt信号通路，会诱导细胞增生，进而导致腺瘤形成。诱发突变（driver mutation）逐渐积累最终导致浸润性肿瘤的形成。如果在早期即可诊断出CRC，五年生存率可达80%以上，如果在晚期，肿瘤细胞已经转移，那五年生存率还不到10%。因此如果能在各个国家进行早期筛

ANN ONCOL：结直肠癌发病部位对患者生存预后的影响

有越来越多的证据表明转移性结直肠癌（mCRC）是一种异质性疾病，不同结肠部位（左侧或右侧）发生的肿瘤有不同的临床结局。针对KRAS野生型或RAS野生型的转移性结直肠癌患者的研究表明原发肿瘤部位对临床结局同时具有预后和预测意义。ANN ONCOL近期发表了一篇文章，研究不同原发肿瘤部位对患者生存预后的影响。

CLIN CANCER RES：NRAS突变结直肠癌患者临床特征及结局

临床进行EGFR抑制剂治疗时常规进行NRAS突变检测。NRAS突变结直肠癌除了对抗EGFR治疗缺乏治疗反应外其他临床特征尚未知。CLIN CANCER RES近期发表了一篇文章，研究NRAS突变转移性结直肠癌患者临床特征和治疗结果。